Today, we announced an important milestone for Fractyl Health and the future of obesity care.
For the first time, randomized, blinded clinical data from the REMAIN-1 Midpoint Cohort demonstrate that Revita® may prevent weight regain after GLP-1 discontinuation at 3 months. In the study, patients treated with Revita continued to lose weight following GLP-1 withdrawal, while sham patients regained weight (–2.5% vs. +10%, p=0.014).
These findings suggest that drug-free, durable weight maintenance may be possible. We believe Revita has the potential to serve as a one-time intervention that could transform the standard of care—much like LASIK did for vision.
The implications are significant: shifting from a focus on temporary weight loss to sustaining health through a durable metabolic reset. With pivotal studies ahead, Revita may help define a new therapeutic category in obesity: post-GLP-1 weight maintenance.
This is just the beginning of the journey.
#FractylForward$GUTS#obesity#weightmaintenance
Revita® is for Investigational Use Only in the U.S. under Federal law.
ir.fractyl.com/news-releases…
1.1 million Americans started in the GLP-1 bridge program…CBO estimates ~65% will stop their GLP-1 within a year. What comes next? beckerspayer.com/payer/medic…
Pleased to share our #OW2026 oral abstract’s full paper in @eClinicalMed. Our study could inform patient-clinician discussions about alternative therapy options in patients who consider switching or stopping semaglutide or tirzepatide.
thelancet.com/action/showPdf…
Weight loss gets the headlines, but what is the plan when treatment stops?
Last week's FDA action on potential risks associated with GLP-1 medicines should widen the conversation about options for long-term obesity care.
On November 9, the agency required labeling changes concerning a potential increased risk of NAION, a rare optic nerve condition that can cause permanent vision loss. In its pooled clinical-trial analysis, FDA reported 6.4 cases per 100,000 person-years with GLP-1s versus 3.8 with comparators. Those are rare events, and the finding warrants careful discussion alongside the substantial benefits these medicines provide.
Separately, ACOG (ob/gyn society) has recently issued guidelines recommending that people should stop GLP-1s before planned pregnancy.
We have been hearing questions from patients and physicians about what these recommendations concerning vision or pregnancy might mean about staying on GLP-1s, and what happens if people need to stop their GLP-1?
Treatment decisions belong with patients and their clinicians. FDA advises patients with new vision symptoms to contact a health care professional right away. The question I want us to address is broader: what is the plan for people who need to discontinue treatment?
We have made remarkable progress in helping people lose weight. We need the same ambition for helping them maintain it through necessary changes in treatment.
The STEP 1 extension illustrates the challenge. One year after semaglutide and the study's lifestyle intervention ended, participants had regained about two-thirds of their prior weight loss.
Maintaining weight loss deserves to be a treatment objective in its own right. A patient who stops a medicine still has a chronic disease that needs care.
That is why, as co-founder and CEO of Fractyl Health, I am focused on post-GLP-1 weight maintenance.
We are studying Revita, an endoscopic duodenal remodeling procedure. In our company-reported six-month REMAIN-1 results, participants retained approximately 80% of prior GLP-1-induced weight loss versus 67% with sham in the modified intention-to-treat analysis (p=0.0023).
That is an encouraging early milestone. The 12-month co-primary endpoint is expected in Q1 2027. The goal of Revita treatment is to help patients maintain their hard won weight loss without as much risk of weight and metabolic rebound if they need to stop the medicine.
My conviction is that obesity care should give patients more evidence-based ways to sustain progress as their treatment needs change.
The next chapter should ask more of every approach: How much weight loss is maintained? For how long? In whom? With what risks?
Getting those answers deserves the same attention as the weight-loss headlines.
Revita is investigational use only in the US.
Sources:
FDA: fda.gov/drugs/drug-safety-co…
STEP 1 extension: pubmed.ncbi.nlm.nih.gov/3544…
REMAIN-1 results: ir.fractyl.com/news-releases…
The next major advance in obesity treatment doesn’t have to be yet another drug.
At Fractyl Health ($GUTS), we’re developing a different approach: treating the gut itself.
Our REMAIN-1 pivotal trial recently demonstrated less weight regain with Revita versus sham, six months after stopping GLP-1 therapy (p=0.0023).
But developing a new medical technology is only part of the challenge. Protecting the innovation matters too.
Today, we announced new intellectual property milestones, including patent protection for our Revita catheter extending to 2042.
Our broader portfolio also includes patents covering certain methods of treating metabolic disease through duodenal ablation, not limited to one energy modality.
Why does that matter?
Because we believe post-GLP-1 weight maintenance could become an important new category of obesity medicine.
We’re working to build both the clinical evidence and the intellectual property foundation to participate in that future.
Revita remains investigational in the US.
$GUTSglobenewswire.com/news-relea…
What if one-third of patients taking GLP-1s would rather have a one-time procedure than remain on medication?
Today, $GUTS shared new research that helps explain why we believe the opportunity for Revita could be substantial.
An estimated 1 million Americans discontinue GLP-1 therapy every month, facing the risk of weight regain.
And in our patient research, 1 in 3 current or recent GLP-1 users preferred a hypothetical one-time procedure over continued medication.
Think about what that means.
Patients aren’t just looking for more ways to lose weight. Many want a way to maintain their progress without taking medication indefinitely.
That’s the unmet need we’re developing Revita to address.
With our positive 6-month pivotal results, we now have clinical evidence supporting Revita’s potential. Today’s research adds another important piece: evidence of patient interest in this kind of treatment.
Our ambition is to help establish an entirely new category in obesity care: post-GLP-1 weight maintenance.
Revita remains investigational in the US.
ir.fractyl.com/news-releases…
Gabriel Iglesias was on Ozempic for about five months. His description is the most honest one I’ve heard.
It worked almost too well. He’d look at food and feel nothing, not disgust, just “I’m good.”
The weight came off. But he watched his shoulders disappear with it. A strong guy, losing the strength he was proud of. Add the constant nausea, and he quit.
The moment he stopped, 20 pounds came back almost immediately.
And here’s the twist: years earlier, he says Ozempic offered him a million-dollar deal to be the face of the brand. He turned it down.
That’s the part nobody puts in the commercial. The drug turns off your hunger. It doesn’t protect your muscle, and it doesn’t fix whatever was driving the eating in the first place.
The gut is much more than a digestive organ. It is a metabolic sensing and signaling system that helps shape how we respond to food, regulate appetite, and control metabolism.
Really enjoyed going deep on this with Andrew Huberman, from gut biology and the microbiome to obesity, GLP-1 therapies, and endoscopic treatments.
Medicare GLP-1 Bridge Program: A Bridge to Where Exactly?
CMS’s Medicare GLP-1 Bridge program launched July 1. It feels like a good time to check in on its progress and its goals.
Through the GLP-1 Bridge program, eligible Part D beneficiaries can get certain GLP-1s for weight management for the next 18 months. The program sits outside traditional Part D coverage and payment. This is the first time Medicare has created a pathway for these drugs purely for weight management.
The name itself implies the temporary nature of this program. This was supposed to be a bridge to a longer-term CMS Part D solution called the BALANCE model, but the longer-term plan is not yet ready. The delay in the BALANCE program is a very instructive lesson in the core challenge in the GLP-1 treatment landscape today. CMS pointed to the need to collect more utilization data; but reporting at the time showed too few Part D plan sponsors were willing to participate, citing uncertainty about utilization and thin real-world evidence. While GLP-1s have no shortage of randomized controlled trial data, insurers care just as much about how the drugs perform in the real world to justify the expense to their members.
Unfortunately, the Congressional Budget Office’s cost estimates do not bode well for broad Medicare coverage for GLP-1s alone. In its October 2024 analysis, the CBO assumed that ~65% of new users in 2026 would complete less than one year of treatment, with another 15-20% dropping off each year after that. In total, the CBO estimated that only 15-20% of users would continue treatment for 5 years.
In other words, if a million Medicare patients start on a GLP-1, roughly 800,000 would stop within 5 years, putting them at risk for rapid weight and metabolic rebound. Discontinuation at this rate creates an unfortunate tragedy of the commons in the Medicare drug budget: the 20% who would benefit long-term are at risk of losing access because of the 80% who would start and stop. It is no surprise Part D sponsors are waiting to see more “real-world data.”
There are two ways to solve this: Either we figure out ahead of time who will stay on GLP-1s and who won’t, or patients who discontinue will need a durable off-ramp to preserve those benefits without staying on drug. The first of these options would control costs, but only by withholding therapy from the 80%. The second option offers hope of improving obesity and related risks for anyone who starts GLP-1s, whether they stay on GLP-1s long term or not.
The Bridge expires at the end of 2027, and whatever replaces it will be shaped by whichever of these two paths we’ve made progress on by then. Durable weight maintenance after GLP-1 discontinuation may be the key to unlocking broader, sustainable access to these therapies. Fixing the tragedy of the commons in GLP-1 therapy isn’t about limiting who gets treated; it’s about making sure anyone who starts can maintain those benefits for the long-term.
People talk about newer GLP-1 agents now achieving bariatric surgery levels of weight loss. But do they really?
New real-world data in Obesity looked at >44,000 patients on semaglutide, tirzepatide, or bariatric surgery.
At 1–3 years:
Semaglutide: ~5–7% total weight loss
Tirzepatide: ~9–11%
Sleeve: ~22–24%
Bypass: ~28–30%
Even patients who managed to stay on continuous GLP-1 therapy for a full year still landed well short of surgery.
Yogi Berra famously said "In theory there is no difference between theory and practice. In practice there is."
The GLP-1 trial results were impressive in theory. The real-world practice, as usual, is less cooperative. The real world is messy - titration, prescription refills, side effects - and all these factors stand in the way of chronic therapy matching clinical trial results.
How do we advise patients? Based on what happened in an idealized clinical trial setting or based on what is observed in real world practice?
@Ali_Aminian_MD@NeilFlochMD@Jmortonmdonlinelibrary.wiley.com/doi/…
While nearly 18% of U.S. adults have taken a GLP-1 drug for weight loss or to treat a chronic condition, about half of people will stop taking it within a year. Often, they don’t understand what is likely to come next. 🔗: on.wsj.com/4dCkbia
Duodenal mucosal resurfacing procedure may offer a way for the estimated 70% of people who discontinue weight-loss drugs to avoid regaining weight, the findings indicate that this minimally invasive procedure may provide lasting weight-loss maintenance tinyurl.com/3zdtawud
Highly recommend this presentation from Dr Ania Jastreboff, lead researcher for many obesity trials, including SURMOUNT-1, which lead to Zepbound’s FDA approval, and the upcoming TRIUMPH-1 trial on retatrutide.
She argues that obesity stems from an inappropriate setting of the defended fat mass by the metabolic system which causes the brain to inappropriately signal for more food consumption because it has incorrectly determined that the individual needs to increase their fat mass.
These meds re-regulate that, resetting the defended fat mass to lower levels, reducing the brains signals to eat more, and allowing individuals to lose weight.
The upcoming retatrutide will not just change appetite/craving signaling, but will also increase energy expenditure itself.
What happens after stopping GLP-1s? That’s the question Revita is designed to answer. New interview with @Medtech_Insight on durability, the duodenum, and the road to pivotal data in early Q4. Revita is investigational use only in the US. Full interview here: insights.citeline.com/medtec…
DDW 2026: Revita highlighted as a potential post-GLP-1 ‘off-ramp’ strategy in DDW News, featuring our REMAIN-1 interim midpoint results. Oral presentation scheduled for Monday, May 4. Full pivotal data targeted later 2026. Revita is investigational use only in the US. @FractylHealth@FractylHealthnews.ddw.org/news/duodenal-m…